Total Payments
$13,336
2024 Payments
$242.06
Companies
24
Transactions
107
Medicare Patients
45,081
Medicare Billing
$14.1M
Payment Breakdown by Category
Other$11,274 (84.5%)
Food & Beverage$2,062 (15.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Current or prospective ownership or investment interest | $11,274 | 7 | 84.5% |
| Food and Beverage | $2,062 | 92 | 15.5% |
| Unspecified | $0 | 8 | 0.0% |
Payments by Type
General
$13,336
99 transactions
Ownership
$0
8 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| US Retina LLC | $11,274 | 15 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $369.80 | 17 | $0 (2024) |
| Genentech USA, Inc. | $357.10 | 18 | $0 (2024) |
| Allergan, Inc. | $291.62 | 9 | $0 (2022) |
| ABBVIE INC. | $193.70 | 9 | $0 (2024) |
| Alimera Sciences, Inc. | $193.70 | 11 | $0 (2024) |
| Astellas Pharma US Inc | $108.34 | 2 | $0 (2023) |
| Stryker Corporation | $106.43 | 1 | $0 (2023) |
| Halozyme Inc | $72.08 | 4 | $0 (2020) |
| Aerie Pharmaceuticals, Inc. | $43.13 | 3 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $242.06 | 11 | Regeneron Healthcare Solutions, Inc. ($83.93) |
| 2023 | $482.94 | 16 | Astellas Pharma US Inc ($108.34) |
| 2022 | $5,040 | 22 | US Retina LLC ($4,661) |
| 2021 | $2,522 | 20 | US Retina LLC ($2,231) |
| 2020 | $1,530 | 7 | US Retina LLC ($1,445) |
| 2019 | $2,097 | 12 | US Retina LLC ($1,895) |
| 2018 | $1,152 | 9 | US Retina LLC ($1,043) |
| 2017 | $269.16 | 10 | Allergan Inc. ($149.40) |
All Payment Transactions
107 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/07/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $22.93 | General |
| Category: EYE CARE | ||||||
| 10/04/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological), EYLEA | Food and Beverage | In-kind items and services | $27.24 | General |
| Category: OPHTHALMOLOGY | ||||||
| 09/23/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $26.88 | General |
| Category: EYE CARE | ||||||
| 09/20/2024 | Alimera Sciences, Inc. | YUTIQ (Drug), ILUVIEN | Food and Beverage | In-kind items and services | $21.92 | General |
| Category: Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye | ||||||
| 07/26/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $22.88 | General |
| Category: Immunology and Ophthalmology | ||||||
| 07/13/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $33.12 | General |
| Category: OPHTHALMOLOGY | ||||||
| 05/10/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $25.95 | General |
| Category: Immunology and Ophthalmology | ||||||
| 04/19/2024 | Alimera Sciences, Inc. | YUTIQ (Drug), ILUVIEN | Food and Beverage | In-kind items and services | $22.57 | General |
| Category: Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye | ||||||
| 04/12/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $23.57 | General |
| Category: OPHTHALMOLOGY | ||||||
| 02/09/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $15.00 | General |
| Category: Immunology and Ophthalmology | ||||||
| 2024 | US Retina LLC | — | — | — | $0.00 | Ownership |
| 12/08/2023 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $21.52 | General |
| Category: OPHTHALMOLOGY | ||||||
| 11/14/2023 | Stryker Corporation | COLORADO (Device), NA, VSP SYSTEM, VSP CRANIAL | Food and Beverage | In-kind items and services | $106.43 | General |
| Category: RF TECH | ||||||
| 09/25/2023 | Astellas Pharma US Inc | — | Food and Beverage | In-kind items and services | $30.30 | General |
| 09/25/2023 | AbbVie Inc. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $25.17 | General |
| Category: EYE CARE | ||||||
| 09/22/2023 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $25.91 | General |
| Category: Immunology and Ophthalmology | ||||||
| 09/15/2023 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $25.73 | General |
| Category: OPHTHALMOLOGY | ||||||
| 09/11/2023 | Astellas Pharma US Inc | — | Food and Beverage | In-kind items and services | $78.04 | General |
| 07/14/2023 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $20.37 | General |
| Category: Immunology and Ophthalmology | ||||||
| 06/29/2023 | PFIZER INC. | BOSULIF (Drug), BESPONSA | Food and Beverage | In-kind items and services | $17.31 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 05/01/2023 | AbbVie Inc. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $17.85 | General |
| Category: EYE CARE | ||||||
| 04/21/2023 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $17.70 | General |
| Category: Immunology and Ophthalmology | ||||||
| 03/10/2023 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $17.03 | General |
| Category: Immunology and Ophthalmology | ||||||
| 02/25/2023 | Regeneron Healthcare Solutions, Inc. | EYLEA (Biological) | Food and Beverage | In-kind items and services | $29.98 | General |
| Category: OPHTHALMOLOGY | ||||||
| 02/03/2023 | Eyevance Pharmaceuticals LLC | TobraDex ST (Drug) | Food and Beverage | In-kind items and services | $23.85 | General |
| Category: OPHTHALMIC | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 35 | 11,411 | 36,243 | $10.8M | $3.8M |
| 2022 | 29 | 11,032 | 25,455 | $10.1M | $3.6M |
| 2021 | 31 | 11,277 | 26,076 | $10.1M | $3.6M |
| 2020 | 33 | 11,361 | 24,871 | $9.2M | $3.0M |
Total Patients
45,081
Total Services
112,645
Medicare Billing
$14.1M
Procedure Codes
128
All Medicare Procedures & Services
128 procedure records from CMS Medicare Utilization — Page 1 of 6
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | Office | 2023 | 198 | 2,516 | $3.7M | $1.7M | 47.0% |
| 67028 | Injection of drug into eye | Office | 2023 | 855 | 4,154 | $1.5M | $380,187 | 25.1% |
| J2777 | Injection, faricimab-svoa, 0.1 mg | Office | 2023 | 37 | 10,381 | $747,360 | $302,123 | 40.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 2,267 | 3,465 | $634,095 | $226,728 | 35.8% |
| 92134 | Imaging of retina | Office | 2023 | 3,036 | 7,328 | $747,456 | $212,543 | 28.4% |
| J7999 | Compounded drug, not otherwise classified | Office | 2023 | 533 | 2,554 | $766,200 | $168,189 | 22.0% |
| 67042 | Removal of membrane of retina with removal of internal limiting membrane of retina | Facility | 2023 | 146 | 154 | $447,986 | $138,120 | 30.8% |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | Office | 2023 | 1,114 | 1,244 | $262,484 | $126,144 | 48.1% |
| J7312 | Injection, dexamethasone, intravitreal implant, 0.1 mg | Office | 2023 | 30 | 415 | $125,139 | $65,572 | 52.4% |
| 92014 | Established patient complete exam of visual system | Office | 2023 | 730 | 742 | $227,794 | $61,171 | 26.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 522 | 650 | $174,850 | $59,751 | 34.2% |
| 67210 | Destruction of growth of retina using a laser | Office | 2023 | 83 | 95 | $128,700 | $38,378 | 29.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 304 | 304 | $125,856 | $38,224 | 30.4% |
| 67039 | Destruction of eye fluid (vitreous) between lens and retina using a laser | Facility | 2023 | 43 | 47 | $114,351 | $35,498 | 31.0% |
| J9035 | Injection, bevacizumab, 10 mg | Office | 2023 | 143 | 630 | $189,000 | $34,895 | 18.5% |
| 67113 | Complex repair of detached retina and drainage of eye fluid between lens and retina | Facility | 2023 | 24 | 30 | $101,460 | $30,506 | 30.1% |
| 67108 | Repair of detached retina with drainage and removal of eye fluid between lens and retina | Facility | 2023 | 33 | 33 | $100,023 | $30,438 | 30.4% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 349 | 349 | $95,212 | $26,922 | 28.3% |
| 67228 | Destruction of leaking blood vessels of retina using laser | Office | 2023 | 48 | 79 | $175,900 | $22,886 | 13.0% |
| 92004 | New patient complete exam of visual system | Office | 2023 | 156 | 156 | $57,720 | $16,914 | 29.3% |
| 67145 | Photocoagulation treatment to prevent detachment of retina | Office | 2023 | 60 | 65 | $85,800 | $12,000 | 14.0% |
| 67041 | Removal of membrane of retina | Facility | 2023 | 13 | 13 | $37,778 | $11,714 | 31.0% |
| 92012 | Established patient problem focused exam of visual system | Office | 2023 | 137 | 154 | $32,648 | $10,507 | 32.2% |
| 67110 | Repair of detached retina by injection of air or gas | Office | 2023 | 17 | 17 | $37,315 | $10,389 | 27.8% |
| 66986 | Exchange of prosthetic lens | Facility | 2023 | 22 | 22 | $50,336 | $9,593 | 19.1% |
About Dr. John Sullivan, MD
Dr. John Sullivan, MD is a Ophthalmology healthcare provider based in Jacksonville, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/22/2005. The National Provider Identifier (NPI) number assigned to this provider is 1619977345.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. John Sullivan, MD has received a total of $13,336 in payments from pharmaceutical and medical device companies, with $242.06 received in 2024. These payments were reported across 107 transactions from 24 companies. The most common payment nature is "Current or prospective ownership or investment interest" ($11,274).
As a Medicare-enrolled provider, Sullivan has provided services to 45,081 Medicare beneficiaries, totaling 112,645 services with total Medicare billing of $14.1M. Data is available for 4 years (2020–2023), covering 128 distinct procedure/service records.
Ad
Practice Information
- Specialty Ophthalmology
- Other Specialties Retina Specialist, Retina Specialist
- Location Jacksonville, FL
- Active Since 07/22/2005
- Last Updated 04/05/2017
- Taxonomy Code 207W00000X
- Entity Type Individual
- NPI Number 1619977345
Products in Payments
- OZURDEX (Drug) $457.51
- EYLEA (Biological) $204.94
- Vabysmo (Drug) $170.59
- EYLEA HD (Biological) $131.18
- COLORADO (Device) $106.43
- VABYSMO (Drug) $86.03
- Lucentis (Biological) $84.76
- Iluvien (Drug) $77.95
- Hylenex (Drug) $72.08
- YUTIQ (Drug) $57.78
- ILUVIEN (Drug) $56.03
- Acuvue (Device) $40.47
- EYLEA AFLIBERCEPT INJECTION (Biological) $33.68
- PROLENSA (Drug) $30.44
- rhopressa (Drug) $28.07
- Briviact (Drug) $27.35
- TobraDex ST (Drug) $23.85
- ZEPOSIA (Drug) $20.39
- BEOVU (Drug) $19.93
- NOURIANZ (Drug) $18.47
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Ophthalmology Doctors in Jacksonville
Syril Dorairaj, Md, MD
Ophthalmology — Payments: $542,154
Ophthalmology $542,154
Jeffrey Levenson, M.d, M.D
Ophthalmology — Payments: $435,025
Ophthalmology $435,025
Dr. Frank Bowden, M.d, M.D
Ophthalmology — Payments: $213,959
Ophthalmology $213,959
David Kostick, Md, MD
Ophthalmology — Payments: $96,443
Ophthalmology $96,443
Benjamin Thomas, Md, MD
Ophthalmology — Payments: $76,189
Ophthalmology $76,189
Ron Adelman, Md, MD
Ophthalmology — Payments: $62,231
Ophthalmology $62,231